

Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication (Ph- MPN (MF, PV, ET), Ph+ CML), By Major Markets, Competitive Landscape, And Segment Forecasts, 2018 - 2023

<https://marketpublishers.com/r/MC45F8A049EEN.html>

Date: August 2018

Pages: 83

Price: US\$ 5,950.00 (Single User License)

ID: MC45F8A049EEN

Abstracts

This report can be delivered to the clients within 72 Business hours

The global myeloproliferative disorder drugs market size is expected to be valued at USD 9.26 billion by 2023, as per a new report by Grand View Research, Inc., expanding at a CAGR of 3.4% during the forecast period. Availability of novel drugs, presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market. Therapeutic development in second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.

Chronic myeloproliferative disorders are rare hematological malignancies that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.

There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group. The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to presence of a large target population.

Further key findings from the report suggest:

The U.S. accounted for more than 45.0% of the market in 2017. Spiraling adoption of novel therapeutics and multiple product launches during the forecast period are anticipated to support the prominence of the market in global arena over the coming years

Strong unmet needs are likely to shape the future of the market and encourage development of breakthrough first-in-class therapies. Opportunities remain in the Ph- MPNs setting where there exists an unmet need for a safer drug than Jakafi with higher cure rates and lesser allergic effects

Some of the key market participants are Novartis, Bristol-Myers Squibb, Pfizer, Takeda, Incyte and Teva. Primary go-to strategies of prominent players include collaborations for development and regional expansion in emerging markets.

Contents

CHAPTER 1 RESEARCH METHODOLOGY

- 1.1. Information Procurement
- 1.2. Information or Data Analysis
 - 1.2.1 Market Formulation & Validation

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY

- 3.1. Disease Primer
- 3.2. Epidemiology

CHAPTER 4 GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS MARKET OVERVIEW

- 4.1 Market by Indication
- 4.2 Market Size and Forecast 2017 - 2023
- 4.3 Market Share Distribution, by Company 2017 - 2023
- 4.4 Market Dynamics and Brand Strategies
- 4.5 Patent Expiry Analysis
- 4.6 Myeloproliferative Disorders Market: Drivers and Restraints
 - 4.6.1 Drivers
 - 4.6.2 Challenges
- 4.7 M&A, Deal Landscape (2013 - 2018 YTD)
 - 4.7.1 Mergers & Acquisitions
 - 4.7.2 Deals Landscape
- 4.8 Reimbursement Scenario
- 4.9 Myeloproliferative Disorders Market: Sector SWOT

CHAPTER 5 MYELOPROLIFERATIVE DISORDERS MARKET: PIPELINE INTELLIGENCE

- 5.1. Pipeline Landscape
 - 5.1.1 Leading Drugs in Development
 - 5.1.2 Key R&D Trends
- 5.2 Pipeline Landscape

- 5.2.1 Late Stage Pipeline and Sales Forecast
- 5.2.2 Profiles of Disruptive Drugs
- 5.3 Global Pipeline Forecast

CHAPTER 6 COMPANY PROFILES

6.1 Novartis

- 6.1.1 Company Overview
- 6.1.2 Current Product Portfolio
- 6.1.3 Product Forecast Sales Through 2023
- 6.1.4 Strategic Initiatives
 - 6.1.4.1 Key Company News Flow
- 6.1.5 Pipeline Analysis & Overview
- 6.1.6 SWOT

6.2 Bristol-Myers Squibb

- 6.2.1 Company Overview
- 6.2.2 Current Product Portfolio
- 6.2.3 Product Forecast Sales Through 2023
- 6.2.4 Strategic Initiatives
 - 6.2.4.1 Key Company News Flow
- 6.2.5 Pipeline Analysis & Overview
- 6.2.6 SWOT

6.3 Pfizer

- 6.3.1 Company Overview
- 6.3.2 Current Product Portfolio
- 6.3.3 Product Forecast Sales Through 2023
- 6.3.4 Strategic Initiatives
 - 6.3.4.1 Key Company News Flow
- 6.3.5 Pipeline Analysis & Overview
- 6.3.6 SWOT

6.4 Takeda

- 6.4.1 Company Overview
- 6.4.2 Current Product Portfolio
- 6.4.3 Product Forecast Sales Through 2023
- 6.4.4 Strategic Initiatives
 - 6.4.4.1 Key Company News Flow
- 6.4.5 SWOT

6.5 Inctye

- 6.5.1 Company Overview

- 6.5.2 Current Product Portfolio
- 6.5.3 Product Forecast Sales Through 2023
- 6.5.4 Strategic Initiatives
 - 6.5.4.1 Key Company News Flow
- 6.5.5 Pipeline Analysis & Overview
- 6.5.6 SWOT

6.6 Teva

- 6.6.1 Company Overview
- 6.6.2 Current Product Portfolio
- 6.6.3 Product Forecast Sales Through 2023
- 6.6.4 Strategic Initiatives
 - 6.6.4.1 Key Company News Flow
- 6.6.5 SWOT

CHAPTER 7 MARKET OUTLOOK

- 7.1 What the Future Holds
- 7.2 The Winners and Losers
 - 7.2.1 Winners
 - 7.2.2 Losers
- 7.3 Emerging Companies & Technology Platforms
- 7.4 The Road Ahead

List Of Tables

LIST OF TABLES

Table 1	Marketed Drugs for Myeloproliferative Disorders
Table 2	Sales Performance by Indication, 2017 -
Table 3	Ph+ CML Sales Performance by Country, in \$ million, 2017 - 2023
Table 4	Ph- MPNs Sales Performance by Country, in \$ million, 2017 - 2023
Table 5	U.S. Ph- MPNs Sales Performance, in \$ million, 2017 - 2023
Table 6	U.K. Ph- MPNs Sales Performance, in \$ million, 2017 - 2023
Table 7	Germany Ph- MPNs Sales Performance, in \$ million, 2017 - 2023
Table 8	France Ph- MPNs Sales Performance, in \$ million, 2017 - 2023
Table 9	Italy Ph- MPNs Sales Performance, in \$ million, 2017 - 2023
Table 10	Spain Ph- MPNs Sales Performance, in \$ million, 2017 - 2023
Table 11	Japan Ph- MPNs Sales Performance, in \$ million, 2017 - 2023
Table 12	Patents Expiry for Current Myeloproliferative Disorders Drugs
Table 13	Annual price estimates of drugs approved for the treatment of CML, by Country
Table 14	R&D Pipeline Overview
Table 15	Late Stage Pipeline
Table 16	Asciminib (ABL001)
Table 17	NiCord
Table 18	Pacritinib
Table 19	Luspatercept (ACE-536)
Table 20	Pipeline Forecast
Table 21	Novartis Sales Forecast, 2017 - 2023
Table 22	Novartis Pipeline
Table 23	Bristol-Myers Squibb Sales Forecast, 2017 - 2023
Table 24	Bristol-Myers Squibb Pipeline
Table 25	Pfizer Sales Forecast, 2017 - 2023
Table 26	Pfizer Pipeline
Table 27	Takeda Sales Forecast, 2017 - 2023
Table 28	Incyte Sales Forecast, 2017 - 2023
Table 29	Incyte Pipeline
Table 30	Teva Sales Forecast, 2017 - 2023

List Of Figures

LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Information Procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value chain based sizing & forecasting
- Fig. 6 QFD modelling for market share assessment
- Fig. 7 Myeloproliferative Disorders Market Share, by Treatment Type, 2017 &
- Fig. 8 Regional Market Size, 2017 & 2023
- Fig. 9 U.S. Myeloproliferative Disorders Drugs Market, \$ million (2017 - 23)
- Fig. 10 U.K. Myeloproliferative Disorders Drugs Market, \$ million (2017 - 23)
- Fig. 11 Germany Myeloproliferative Disorders Drugs Market, \$ million (2017 - 23)
- Fig. 12 France Myeloproliferative Disorders Drugs Market, \$ million (2017 - 23)
- Fig. 13 Italy Myeloproliferative Disorders Drugs Market, \$ million (2017 - 23)
- Fig. 14 Spain Myeloproliferative Disorders Drugs Market, \$ million (2017 - 23)
- Fig. 15 Japan Myeloproliferative Disorders Drugs Market, \$ million (2017 - 23)
- Fig. 16 Ph+ CML Market Shares Distribution, 2017 & 2023
- Fig. 17 Ph- MPNs Market Shares Distribution, 2017 & 2023
- Fig. 18 Myeloproliferative Disorders SWOT
- Fig. 19 Myeloproliferative Disorders Pipeline Distribution
- Fig. 20 Novartis Myeloproliferative Disorders Sales Forecast
- Fig. 21 Novartis SWOT Analysis
- Fig. 22 Bristol-Myers Squibb Myeloproliferative Disorders Sales Forecast
- Fig. 23 Bristol-Myers Squibb SWOT Analysis
- Fig. 24 Pfizer Myeloproliferative Disorders Sales Forecast
- Fig. 25 Pfizer SWOT Analysis
- Fig. 26 Takeda Myeloproliferative Disorders Sales Forecast
- Fig. 27 Takeda SWOT Analysis
- Fig. 28 Incyte Myeloproliferative Disorders Sales Forecast
- Fig. 29 Incyte SWOT Analysis
- Fig. 30 Teva Myeloproliferative Disorders Sales Forecast
- Fig. 31 Teva SWOT Analysis

I would like to order

Product name: Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication (Ph- MPN (MF, PV, ET), Ph+ CML), By Major Markets, Competitive Landscape, And Segment Forecasts, 2018 - 2023

Product link: <https://marketpublishers.com/r/MC45F8A049EEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MC45F8A049EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970